ClinicalTrials.gg
CompletedNCT05363774Updated Dec 31, 2025

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

A Phase 1 interventional study of NNC0519-0130 and Placebo (NNC0519-0130) in Healthy Volunteers (Diabetes Mellitus, Type 2), sponsored by Novo Nordisk A/S. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.

Enrollment
210th of 494
161 · median 87
Started
2022
with 1 other
Phase 1
206 of 642
1 open now
Registered
640th of 642
by date

Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 210th largest by enrollment of the 494 interventional ones that give a count, is one of 2 that started in 2022, is one of 206 in phase 1, and was the 640th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 642 studies in Diabetes Mellitus by Novo Nordisk A/S, or all of them as a file.
02

Study summary

NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes, as it is expected to lower elevated sugar levels in the blood. The medicine may also lower the appetite. This could help reducing overweight which is often present in participants with type 2 diabetes. In this study NNC0519-0130 is given to humans for the first time. This study will be looking into how safe the new medicine NNC0519-0130 is and will measure its concentrations in the blood. Moreover, effects on blood sugar, blood fat and body weight will be tested. There are different study parts with different participants. Healthy participants (men), healthy participants (men) with high body weight and people with diabetes (men and women) take part. Single doses and multiple doses are tested and the medicine is studied as an injection or when given orally (as a tablet). The participants are invited to take part in a part of the study which will look at the effects of weekly injected doses of NNC0519-0130 taken over the course of several weeks. It is planned that participants will be given the study medicine once weekly. The dose will be increased every three weeks, if safety and tolerability allow. Participants will take up to six different dose levels. This means that the period with weekly injections of study medicine will in total last up to 18 weeks. Participants will either get the study medicine NNC0519-0130 or placebo (a 'dummy' medicine that looks like the medicines but without any active medicine). Which medicine participant gets is decided by chance. The injection of study medicine will be done by trained staff into the tissue underneath the skin of belly using a syringe and needle. The total duration of the study could last up to 25 weeks.

03

Conditions studied

  • Healthy Volunteers (Diabetes Mellitus, Type 2)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Single ascending dose (SAD) part:
  • Male aged 18-55 years (both inclusive) at screening
  • between 18.5 kilogram per meter square (kg/m\^2) and 27.0 kg/m\^2 (both inclusive) at screening
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator
  • Multiple ascending dose (MAD) part (MAD QD and MAD QW):
  • Male aged 18-55 years (both inclusive) at screening
  • Body mass index between 25.0 kg/m\^2 and 39.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
  • Type 2 diabetes (T2D) part:
  • Female of non- or male aged 18-64 years (both inclusive) at screening
  • Body mass index between 25.0 kg/m\^2 and 39.9 kg/m\^2 (both inclusive) at screening
  • Diagnosed with type 2 diabetes mellitus greater than or equal to (≥) 180 days before screening
  • Treatment naive to antidiabetic drugs or on a stable daily dose(s) of metformin therapy (any metformin formulation any dose) greater than or equal to (>=) 60 days before screening
  • Insulin naive. However, short-term insulin treatment for a maximum of 14 days before screening is allowed, as is prior insulin treatment for gestational diabetes
  • in the range of 6.5% (inclusive) and 9.5% (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Single ascending dose (SAD) part:
  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • Glycosylated () greater than or equal to (≥) 6.5 % (48 millimoles per mole (mmol/mol)) at screening
  • Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • Presence or history of any respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions
  • HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening
  • Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
  • Multiple ascending dose (MAD) part (MAD QD and MAD QW):
  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions
  • HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening
  • Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
  • Type 2 diabetes (T2D) part:
  • Any disorder, except for conditions associated with T2D, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus)
  • Current treatment with systemically effective , monoamine oxidase (MAO) inhibitors, systemic non-selective beta-blockers, growth hormone, non-routine vitamins or herbal products
  • Current treatment with selected oral medication with a narrow therapeutic window, such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and anticonvulsants
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Single ascending dose (SAD) part

    Participants will receive up to six dose levels of subcutaneous NNC0519-0130 or matching placebo in a sequential manner with the dose increasing between cohorts.

    Drug: NNC0519-0130 · Drug: Placebo (NNC0519-0130)

  • Experimental
    Multiple ascending dose (MAD) QD part

    MAD QD part comprises two cohorts in participants with overweight or obesity and a cohort in participants with type 2 diabetes (T2D). The participants in first cohort will receive NNC0519-0130 or matching placebo subcutaneously up to 5 dose levels, and the participants in the second MAD QD cohort will receive NNC0519-0130 or matching placebo orally up to 5 dose levels.

    Drug: NNC0519-0130 · Drug: Placebo (NNC0519-0130)

  • Experimental
    Type 2 diabetes (T2D) part

    Participants will receive NNC0519-0130 or matching placebo up to 2 dose levels with dose escalation within the cohort.

    Drug: NNC0519-0130 · Drug: Placebo (NNC0519-0130)

  • Experimental
    MAD QW part

    MAD QW part comprises two cohorts in participants with overweight or obesity and who are otherwise generally healthy. The participants in first cohort will receive NNC0519-0130 and 2nd cohort will receive matching placebo subcutaneously up to 6 dose levels.

    Drug: NNC0519-0130 · Drug: Placebo (NNC0519-0130)

Interventions

  • SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts. MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.

  • DrugPlacebo (NNC0519-0130)

    SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts. MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive Placebo up to 6 dose levels.

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part

    Measured as Number of events

    Time frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 22 days)

  2. Number of treatment emergent adverse events (TEAE) in the Multiple ascending dose with daily dosing (MAD QD) subcutaneous cohort

    Measured as Number of events

    Time frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 133 days)

  3. Number of treatment emergent adverse events (TEAE) in MAD QW s.c. cohort

    Measured as Number of events

    Time frame: From time of first dosing (day 1) until completion of the follow-up visit (assessed up to 133 days)

  4. Number of treatment emergent adverse events (TEAE) in T2D QW cohort

    Measured as number of events

    Time frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 133 days)

Secondary outcomes

  1. AUC0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve from time 0 (time of dosing) to infinity after a single dose

    Measured in h\*nmol/L

    Time frame: From pre-dose (day 1) until completion of the follow-up visit (assessed up to 22 days)

  2. Cmax,NNC0519-0130,SD: Maximum plasma concentration of NNC0519-0130 after a single dose

    Measure in nmol/L

    Time frame: From pre-dose (day 1) until completion of the follow-up visit (assessed up to 22 days)

  3. Number of treatment emergent adverse events (TEAE) in the MAD QD oral cohort

    Measured as Number of events

    Time frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 112 days)

  4. AUC0-24h,NNC0519-0130,SS: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment period in MAD QD part

    Measured in h\*nmol/L

    Time frame: From pre-dose (last dose in each treatment period) until 24 hours post-dose

  5. Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period in MAD QD part

    Measured in nmol/L

    Time frame: From pre-dose (last dose in each treatment period) until 24 hours postdose

  6. AUC0-168h,NNC0519-0130,MD: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in T2D QW cohort

    Measured in h\*nmol/L

    Time frame: From pre-dose (last dose) until 168 hours post-dose

  7. Cmax,NNC0519-0130,MD: Maximum plasma concentration of NNC0519-0130 after the last dose in T2D QW cohort

    Measured in nmol/L

    Time frame: From pre-dose (last dose) until 168 hours post-dose

  8. AUC0-168h,NNC0519-0130,SS: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment period in the MAD QW s.c. cohort

    measured in h\*nmol/L

    Time frame: From pre-dose (last dose in each treatment period) until 168 hours post-dose

  9. Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period in the MAD QW s.c. cohort

    Measured in nmol/L

    Time frame: From pre-dose (last dose in each treatment period) until 168 hours post-dose

07

Study locations

3 sites
  • Novo Nordisk Investigational Site
    Søborg, 2860, Denmark
  • Profil GmbH & Co. KG
    Mainz, 55116, Germany
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, 41460, Germany
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Apr 2024, 23 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 23 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2022
First posted
May 6, 2022
StartActual
Apr 20, 2022
Primary completionActual
Apr 2, 2024
CompletionActual
Apr 2, 2024
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05363774
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 6, 2022
Start date
Apr 20, 2022
Primary completion
Apr 2, 2024
Completion
Apr 2, 2024
Last update
Dec 31, 2025

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0519-0130

Start the discussion